2006
Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience
Muss H, Berry D, Cirrincione C, Budman D, Henderson I, Citron M, Norton L, Winer E, Hudis C. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. Journal Of Clinical Oncology 2006, 24: 559-559. DOI: 10.1200/jco.2006.24.18_suppl.559.Peer-Reviewed Original ResearchAML/MDSNon-hematologic toxicitiesBreast cancerOlder ptsYounger ptsNode-positive breast cancerIntensive adjuvant chemotherapyAge-adjusted ratesStrict eligibility criteriaAdjuvant chemotherapyHematologic toxicityMajor toxicitySurvival benefitYounger patientsCardiac deathClinical trialsGrade 3Eligibility criteriaHigh incidenceNormal populationIncidenceDeathTrialsRegimensSignificant differences
2004
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342. Journal Of Clinical Oncology 2004, 22: 2061-2068. PMID: 15169793, DOI: 10.1200/jco.2004.08.048.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerQuality of lifeOptimal doseResponse rateSignificant dose-response relationshipHigh-dose armPrior chemotherapy regimensHigh-dose therapySymptom assessment questionnaireCycles of treatmentSelf-administered qualitySignificant differencesDose-response relationshipChemotherapy regimensDose therapyHematologic toxicityDose armAssessment QuestionnaireHigh dosesMultivariate analysisSignificant associationInfusionCancerRegimens
2002
Complementary and alternative medicine use among women with breast cancer.
DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. Journal Of Clinical Oncology 2002, 20: 34s-8s. PMID: 12235222.Peer-Reviewed Original ResearchConceptsAlternative medicine useBreast cancer patientsCAM useBreast cancerCancer patientsMedicine useForm of CAMLittle scientific evidenceSocial support groupsTreatment regimensCancer preventionPsychosocial distressGeneral populationPsychosocial interventionsVariety of modalitiesDietary supplementsPatientsCancerSupport groupsWomenScientific evidenceBehavioral techniquesInterventionRegimensCAM
2001
Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
Partridge A, Burstein H, Winer E. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. JNCI Monographs 2001, 2001: 135-142. PMID: 11773307, DOI: 10.1093/oxfordjournals.jncimonographs.a003451.Peer-Reviewed Original ResearchConceptsLong-term side effectsSide effectsChemohormonal therapyAdjuvant chemotherapyShort-term side effectsEarly-stage breast cancerSide effect profileDuration of treatmentLong-term toxicityAdjuvant regimenLate complicationsEffect profileTherapy regimensBreast cancerChemotherapySpecific agentsTherapyToxic effectsPossible risksTreatmentPotential benefitsConsiderable variabilityRegimenRegimensComplications